Gilead Sciences Approved to Market HCV Drug in China
September 25, 2017 at 05:19 AM EDT
Gilead Sciences of the US received CFDA approval for Sovaldi ® , its once-daily oral treatment for chronic hepatitis C. Last year, Gilead began building a China commercial operation in Shanghai in preparation for the approval. The Shanghai office joins Gilead's regulatory team in Beijing , a chemical manufacturing outsourcing group in Shanghai , and a new manufacturing facility under construction in Hangzhou , the company's first plant outside the US . Gilead must still address the issue of Sovaldi's price in China : in the US , a three-month treatment regimen costs close to $100,000. More details.... Stock Symbol: (NSDQ: GILD) Share this with colleagues: // //